Ipamorelin Research: Identity, Published Studies and COAs

Ipamorelin is a synthetic pentapeptide studied as a growth hormone secretagogue. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, including histidine at position two. For laboratory research, material identity, the experimental model and batch documentation should be reviewed separately from claims about biological effects.

Vertex Labs supplies Ipamorelin 10 mg research peptide. Review the product specifications and the corresponding report in the batch COA directory before selecting material for a laboratory workflow.

What is Ipamorelin?

The 1998 characterization study describes Ipamorelin as a five-residue peptide and examines growth hormone release in rat pituitary cells, rats and swine. In the swine experiments, its ACTH and cortisol responses were not significantly different from those following GHRH stimulation. That is a finding within the tested models, not a general guarantee of endocrine selectivity or safety in people.

When checking a material specification, include the complete sequence and terminal notation. The shortened sequence Aib-D-2-Nal-D-Phe-Lys-NH2 omits histidine and does not represent the five-residue sequence reported in that study.

What does published human research show?

Pharmacokinetic and pharmacodynamic research

A 1999 study in healthy male volunteers measured Ipamorelin concentrations and growth hormone responses following intravenous infusion. The authors reported dose-proportional pharmacokinetics and a terminal half-life of approximately two hours under those study conditions.

It is therefore inaccurate to say that no human pharmacokinetic study exists. These results characterize the tested route and population; they do not establish parameters for another route, a chronic-use regimen or a commercial research vial.

Postoperative gastrointestinal recovery

A 2014 randomized, placebo-controlled proof-of-concept trial examined gastrointestinal recovery after bowel surgery. It enrolled 117 patients, with 114 included in the safety and modified intention-to-treat populations. The study found no statistically significant differences in the key or secondary efficacy analyses.

This result should be described for that indication and study design. It neither establishes a therapeutic benefit nor supports treating a limited trial’s tolerability findings as a comprehensive safety profile.

How to interpret Ipamorelin research

Separate three questions when reviewing a publication: what material was tested, what the experiment measured and what the result supports. Receptor or hormone-response experiments, pharmacokinetic studies and clinical efficacy trials answer different questions. Evidence from one category should not be presented as proof of another.

• Record the test material, model, route or assay conditions, comparison group and endpoint.
• Distinguish a statistically significant result from a numerical trend.
• Keep findings tied to the tested compound and formulation.
• Use primary publications to verify claims rather than repeating summaries without checking their sources.

Ipamorelin alone vs a CJC-1295 blend

A single-compound Ipamorelin vial and a CJC-1295 No DAC + Ipamorelin blend have different compositions. A paper studying one compound alone does not validate a combined formulation.

See Ipamorelin vs CJC-1295 for the compound and formulation distinction. The CJC-1295 No DAC + Ipamorelin blend listing describes 5 mg of each component, for 10 mg total labeled peptide content. Review its own batch documentation separately from the individual Ipamorelin product.

What to check in an Ipamorelin COA

Open the Ipamorelin certificate of analysis for lot IP0000031 to access its original report. Match the batch on your material before interpreting the results. This record does not establish which lot is currently shipping and does not verify a CJC-1295 or Tesamorelin blend containing Ipamorelin.

Use the guide to reading a peptide COA for report examples and the identity and sequence verification guide for the limits of each analytical method.

Start with the product identity and lot number, then read the scope of the report rather than assuming a standard set of tests:

• Sample match: confirm the product, labeled amount and lot identifier correspond to the material selected.
• Reported testing: check the methods and results actually included in the report.
• Measurement scope: distinguish reported purity, identity and quantity measurements; do not treat them as interchangeable.
• Project requirements: clarify any required measurement or supporting document that is not provided.

A research publication is not a batch certificate, and a batch certificate does not demonstrate biological efficacy. Consult the COA directory and testing standards alongside the selected product’s documentation.

Handling and analytical planning

Follow the product label, applicable safety documentation and your institution’s laboratory procedures. Claims about solution stability, degradation products or analytical sensitivity should be supported for the exact material, matrix and conditions under review. Do not infer a storage window from a biological half-life or assume that a method validated for one matrix transfers unchanged to another.

Frequently asked questions

What is the Ipamorelin sequence?

Aib-His-D-2-Nal-D-Phe-Lys-NH2. The histidine residue is part of the complete five-residue sequence.

Does published human pharmacokinetic research exist?

Yes. The 1999 study linked above reports pharmacokinetic and growth hormone response measurements in healthy volunteers. Its findings remain specific to that study design.

Where can researchers review the 10 mg product and its COA?

The Ipamorelin product page provides material specifications and access to batch documentation. Confirm the lot associated with the material you are evaluating.

Research use only. Vertex Labs products are for laboratory research, not human consumption or veterinary use. This guide provides no dosing, administration or reconstitution instructions.